|
|
||||||||



*
Unidad de Investigacion, Hospital San Pedro de Alcantara, Caceres, Spain; and
Department of Immunology, Holland Laboratory, American Red Cross, Rockville, MD 20855
Allergic diseases, including asthma, represent a major threat to human health. Over the three last decades, their incidence has risen in western countries. Aspirin treatment has been shown to improve allergic diseases, especially asthma, and the decreased use of aspirin has been hypothesized to contribute to the increase in childhood asthma. Because salicylate compounds suppress a number of enzymatic activities, and signaling through IL-4R participates in the development of allergic responses, we tested the effect of salicylates on IL-4 signal transduction. We found that treatment of cell lines and primary cells with aspirin and salicylates, but not acetaminophen, inhibited the activation of STAT6 by IL-4 and IL-13. This effect correlated with the inhibition of IL-4-induced CD23 expression. Although salicylates inhibited the in vivo activation of Janus kinases, their kinase activity was not affected in vitro by salicylates, suggesting that other kinases were involved in IL-4-induced STAT6 activation. Furthermore, we found that an Src kinase was involved in STAT6 activation because 1) Src kinase activity was induced by IL-4, 2) Src kinase activity, but not Janus kinase, was inhibited by salicylates in vitro, 3) cells expressing viral Src had constitutive STAT6 phosphorylation, and 4) cells lacking Src showed low STAT6 phosphorylation in response to IL-4. Because STAT6 activation by IL-4 and IL-13 participates in the development of allergic diseases, our results provide a mechanism to explain the beneficial effects of aspirin and salicylate treatment of these diseases.
This article has been cited by other articles:
![]() |
T Kurth, R G Barr, J M Gaziano, and J E Buring Randomised aspirin assignment and risk of adult-onset asthma in the Women's Health Study Thorax, June 1, 2008; 63(6): 514 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Cortes, M. Perez-G, M. D. Rivas, and J. Zamorano Kaempferol Inhibits IL-4-Induced STAT6 Activation by Specifically Targeting JAK3 J. Immunol., September 15, 2007; 179(6): 3881 - 3887. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Parameswaran, K. Radford, A. Fanat, J. Stephen, C. Bonnans, B. D. Levy, L. J. Janssen, and P. G. Cox Modulation of Human Airway Smooth Muscle Migration by Lipid Mediators and Th-2 Cytokines Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 240 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Roman, A. F. de Arriba, S. Barron, P. Michelena, M. Giral, M. Merlos, E. Bailon, M. Comalada, J. Galvez, A. Zarzuelo, et al. UR-1505, a New Salicylate, Blocks T Cell Activation through Nuclear Factor of Activated T Cells Mol. Pharmacol., August 1, 2007; 72(2): 269 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Barr, T. Kurth, M. J. Stampfer, J. E. Buring, C. H. Hennekens, and J. M. Gaziano Aspirin and Decreased Adult-Onset Asthma: Randomized Comparisons from the Physicians' Health Study Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 120 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. De Santo, P. Serafini, I. Marigo, L. Dolcetti, M. Bolla, P. Del Soldato, C. Melani, C. Guiducci, M. P. Colombo, M. Iezzi, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination PNAS, March 15, 2005; 102(11): 4185 - 4190. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zamorano, M. D. Rivas, F. Setien, and M. Perez-G Proteolytic Regulation of Activated STAT6 by Calpains J. Immunol., March 1, 2005; 174(5): 2843 - 2848. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aceves, A. Duenas, C. Gomez, E. San Vicente, M. S. Crespo, and C. Garcia-Rodriguez A New Pharmacological Effect of Salicylates: Inhibition of NFAT-Dependent Transcription J. Immunol., November 1, 2004; 173(9): 5721 - 5729. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zamorano, M. D. Rivas, A. Garcia-Trinidad, C.-K. Qu, and A. D. Keegan Phosphatidylcholine-Specific Phospholipase C Activity Is Necessary for the Activation of STAT6 J. Immunol., October 15, 2003; 171(8): 4203 - 4209. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Kelly-Welch, E. M. Hanson, M. R. Boothby, and A. D. Keegan Interleukin-4 and Interleukin-13 Signaling Connections Maps Science, June 6, 2003; 300(5625): 1527 - 1528. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |